Short Interest in Interpace Biosciences, Inc. (OTCMKTS:IDXG) Decreases By 77.9%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a significant decrease in short interest in April. As of April 30th, there was short interest totaling 616 shares, a decrease of 77.9% from the April 15th total of 2,793 shares. Based on an average daily volume of 10,517 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.

Interpace Biosciences Trading Down 5.0%

Shares of IDXG traded down $0.10 during mid-day trading on Wednesday, hitting $1.90. 7,825 shares of the company traded hands, compared to its average volume of 8,441. The stock has a market capitalization of $8.42 million, a price-to-earnings ratio of -95.00 and a beta of 0.65. The business has a 50-day moving average of $1.90 and a 200 day moving average of $1.52. Interpace Biosciences has a one year low of $0.70 and a one year high of $2.40.

Interpace Biosciences (OTCMKTS:IDXG) last announced its quarterly earnings data on Tuesday, May 12th. The business services provider reported $0.03 EPS for the quarter. The firm had revenue of $9.03 million for the quarter. Interpace Biosciences had a return on equity of 493.02% and a net margin of 63.46%.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.